Why the study?
Venous thromboembolism is a significant concern in patients with cancer, who face heightened risks of developing and dying from the disease, often requiring multidisciplinary management.
The NCCN Guidelines provide comprehensive recommendations for the prevention, diagnosis, and treatment of cancer-associated venous thromboembolic disease.
Answers are grounded in this paper and cite their sources.
Supports routine VTE risk assessment and prophylaxis in oncology; extends prior consensus to inpatients and outpatients.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Cancer-Associated Venous Thromboembolic Disease focus on the prevention, diagnosis, and treatment of patients with cancer who have developed or who are at risk for developing venous thromboembolism (VTE). VTE is a significant concern among cancer patients, who are at heightened risks for developing as well as dying from the disease. The management of patients with cancer with VTE often requires multidisciplinary efforts at treating institutions. The NCCN panel comprises specialists from various fields: cardiology, hematology/hematologic oncology, internal medicine, interventional radiology, medical oncology, pharmacology/pharmacy, and surgery/surgical oncology. This article focuses on VTE prophylaxis for medical and surgical oncology inpatients and outpatients, and discusses risk factors for VTE development, risk assessment tools, as well as management methods, including pharmacological and mechanical prophylactics. Contraindications to therapeutic interventions and special dosing, when required, are also discussed.
No takes yet. Share an insight, caveat, or question.
Streiff et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: